Treatment of myasthenia--I.
D000324:Adrenocorticotropic Hormone / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D001984:Bronchial Neoplasms / Q000175:diagnosis; D002277:Carcinoma / Q000175:diagnosis; D002800:Cholinesterase Inhibitors / Q000009:adverse effects; D003937:Diagnosis, Differential; D004809:Ephedrine / Q000627:therapeutic use; D006801:Humans; D009135:Muscular Diseases / Q000175:diagnosis; D009157:Myasthenia Gravis / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D009388:Neostigmine / Q000627:therapeutic use; D009469:Neuromuscular Junction / Q000503:physiopathology; D011729:Pyridostigmine Bromide / Q000627:therapeutic use; D013934:Thymectomy
D002800:Cholinesterase Inhibitors; D009388:Neostigmine; D000324:Adrenocorticotropic Hormone; D004809:Ephedrine; D011729:Pyridostigmine Bromide; D001379:Azathioprine